News | Molecular Imaging | January 10, 2022

Vital medical isotope is used in over 40,000 medical procedures in the United States each day

NNSA’s lease contract will provide SHINE with the low-enriched uranium necessary to produce Mo-99 while DOE-EM’s contract details requirements surrounding the return of any resulting radioactive waste unable to be disposed of commercially once Mo-99 production is complete.

Janaury 10, 2022 — The Department of Energy’s National Nuclear Security Administration (NNSA) and Office of Environmental Management (DOE-EM) have signed the first contracts as part of the Department’s Uranium Lease and Take-back Program with SHINE Technologies LLC. This is a milestone in the Department’s effort to increase domestic production of molybdenum-99 (Mo-99), a crucial medical isotope used in over 40,000 medical procedures in the United States each day, without the use of highly enriched uranium (HEU).

NNSA’s lease contract will provide SHINE with the low-enriched uranium necessary to produce Mo-99 while DOE-EM’s contract details requirements surrounding the return of any resulting radioactive waste unable to be disposed of commercially once Mo-99 production is complete.

“Signing these contracts with SHINE is a crucial step toward medical isotope autonomy for the United States,” said Corey Hinderstein, NNSA Deputy Administrator for Defense Nuclear Nonproliferation. “Once SHINE begins production, our country will be that much closer to creating a reliable and sufficient supply of these life-saving materials right here at home, while also increasing nuclear security by reducing the use of highly enriched uranium.”

The American Medical Isotopes Production Act of 2012 directed DOE/NNSA to establish a program to make uranium available to medical isotope producers in the United States. Although the Act also requires DOE to establish take-back contracts for spent nuclear fuel and radioactive waste resulting from medical isotope production without a disposal path, there is no spent fuel involved in these contracts.

NNSA’s Mo-99 program works to ensure a stable, domestic supply of this critical isotope while also reducing the use of HEU in Mo-99 production. Reducing the use of HEU increases nuclear security because HEU could be used in creating a nuclear or radiological weapon.

SHINE Technologies, LLC, of Janesville, Wisconsin, is one of NNSA’s cooperative agreement partners. In October 2021, NNSA awarded SHINE $35 million to support their efforts to produce Mo-99 commercially by the end of 2023.

To establish a reliable domestic Mo-99 production base in the United States, NNSA has also provided financial assistance to potential medical isotope producers. NNSA has implemented this by competitively awarding cost-shared cooperative agreements to commercial entities as well as providing funds to DOE’s National Laboratories to support development of non-HEU Mo-99 production technologies.

Click here for more information on NNSA efforts to establish a reliable supply of Mo‑99 without the use of HEU.

For more information: www.energy.gov/nnsa/national-nuclear-security-administration

Related Isotope Production News:

Shine Medical Approved to Build Domestic Molybdenum-99 Production Facility

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method

Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

World Record for Strongest Nuclear Fusion Reaction in a Steady-State System Achieved by Phoenix and Shine

Molecular Imaging Market to Reach $6.18 Billion


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Over the past several years, technological advancements have driven the development of more precise and targeted ...

Time January 16, 2024
arrow
Subscribe Now